DOVOBET

This brand name is authorized in Canada, Cyprus, Ireland, Italy, Japan, Netherlands, South Africa, UK.

Active ingredients

The drug DOVOBET contains a combination of these active pharmaceutical ingredients (APIs):

1	Calcipotriol monohydrate UNII S7499TYY6G - CALCIPOTRIENE MONOHYDRATE
	Calcipotriol is a derivative of vitamin D for topical use on psoriasis. It probably works by suppressing keratinization. Advantage of substance or absence of odor and non-coloring of clothing.
	Read more about Calcipotriol
2	Betamethasone UNII 826Y60901U - BETAMETHASONE DIPROPIONATE
	Betamethasone is a glucocorticoid which is about eight to ten times as active as prednisolone on a weight-for-weight basis. Betamethasone has anti-inflammatory, antipruritic, and vasoconstrictive properties.
	Read more about Betamethasone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
DOVOBET Gel	MPI, EU: SmPC	Health Products Regulatory Authority (IE)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D05AX52	Calcipotriol, combinations	D Dermatologicals → D05 Antipsoriatics → D05A Antipsoriatics for topical use → D05AX Other antipsoriatics for topical use
Discover more medicines within D05AX52

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02244126, 02319012
GB	Medicines & Healthcare Products Regulatory Agency	176450, 176452, 232874, 33901, 376312, 379717, 381294, 381295, 48706
IE	Health Products Regulatory Authority	13689, 22103, 44615
IT	Agenzia del Farmaco	035675141
JP	医薬品医療機器総合機構	2699802M1024, 2699802Q1026, 2699802R1021
NL	Z-Index G-Standaard, PRK	89761
ZA	Health Products Regulatory Authority	37/13.9.1/0241, 46/13.9.1/0615